We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease.
- Authors
Ho-Su Lee; Kyung-Wook Jo; Tae Sun Shim; Jin Woo Song; Hyo Jeong Lee; Sung Wook Hwang; Sang Hyoung Park; Dong-Hoon Yang; Kyung-Jo Kim; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Jin-Ho Kim; Suk-Kyun Yang
- Abstract
Background and Aims: Limited data are available regarding the pulmonary toxicity of anti-tumour necrosis factor (anti-TNF) therapy for inflammatory bowel disease (IBD). Methods: We retrospectively searched the IBD registry of Asan Medical Center in order to identify patients with lung injury following anti-TNF therapy. Results: Among 1002 patients who were treated using anti-TNF therapy, six cases (0.6%) of anti- TNF-induced lung injury (ATILI) were identified. ATILI was observed soon after the beginning of anti-TNF therapy (two to four doses of anti-TNF). All of these patients experienced improvements in their respiratory symptoms and radiographic findings once the anti-TNF therapy was discontinued. One patient who suffered ATILI following adalimumab was switched to subsequent infliximab and was without recurrence of ATILI. Conclusion: Clinicians should be vigilant regarding the possibility of ATILI in IBD patients treated with anti-TNF agents.
- Publication
Journal of Crohn's & Colitis, 2015, Vol 9, Issue 11, p1053
- ISSN
1873-9946
- Publication type
Article
- DOI
10.1093/ecco-jcc/jjv135